Cassava Sciences (SAVA) Projected to Post Quarterly Earnings on Tuesday

Cassava Sciences (NASDAQ:SAVA) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Cassava Sciences to post earnings of ($0.30) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.

Cassava Sciences Stock Performance

Shares of Cassava Sciences stock opened at $2.28 on Monday. The company has a market capitalization of $110.15 million, a P/E ratio of -1.04 and a beta of -0.85. Cassava Sciences has a 1 year low of $1.15 and a 1 year high of $4.98. The company’s fifty day moving average is $2.12 and its two-hundred day moving average is $2.68.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Cassava Sciences in a report on Friday, December 26th. Wall Street Zen downgraded Cassava Sciences from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $2.00.

Hedge Funds Weigh In On Cassava Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. purchased a new position in shares of Cassava Sciences during the 4th quarter worth approximately $36,000. Jump Financial LLC acquired a new position in Cassava Sciences during the second quarter worth $50,000. Price T Rowe Associates Inc. MD acquired a new position in Cassava Sciences during the fourth quarter worth $63,000. Engineers Gate Manager LP raised its position in Cassava Sciences by 121.1% in the fourth quarter. Engineers Gate Manager LP now owns 31,654 shares of the company’s stock worth $63,000 after acquiring an additional 17,335 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Cassava Sciences by 53,154.9% in the fourth quarter. Barclays PLC now owns 48,462 shares of the company’s stock valued at $96,000 after acquiring an additional 48,371 shares during the period. Institutional investors and hedge funds own 38.05% of the company’s stock.

About Cassava Sciences

Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.

The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients.